A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

Trial Profile

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs INCB 053914 (Primary)
  • Indications Acute myeloid leukaemia; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 12 Dec 2017 Results (n=39; data cut off: 14 April 2017) assessing preliminary safety, pharmacokinetics and pharmacodynamics from part 1, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 16 May 2017 Planned number of patients changed from 135 to 270.
    • 16 May 2017 Planned End Date changed from 1 Oct 2017 to 1 Jan 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top